Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | STTK |
---|---|---|
09:32 ET | 10451 | 1.3 |
09:34 ET | 3583 | 1.28 |
09:36 ET | 744 | 1.29 |
09:38 ET | 4550 | 1.27 |
09:39 ET | 4200 | 1.265 |
09:43 ET | 2864 | 1.2601 |
09:45 ET | 3845 | 1.25 |
09:48 ET | 5752 | 1.255 |
09:50 ET | 2921 | 1.2501 |
09:52 ET | 2413 | 1.25 |
09:54 ET | 1995 | 1.255 |
09:56 ET | 4258 | 1.255 |
09:57 ET | 23627 | 1.25 |
09:59 ET | 6526 | 1.25 |
10:01 ET | 46525 | 1.2347 |
10:03 ET | 40343 | 1.23 |
10:06 ET | 10329 | 1.234 |
10:08 ET | 1462 | 1.24 |
10:10 ET | 1042 | 1.245 |
10:12 ET | 500 | 1.24 |
10:14 ET | 685 | 1.235 |
10:15 ET | 1225 | 1.2301 |
10:17 ET | 2358 | 1.24 |
10:19 ET | 5200 | 1.245 |
10:21 ET | 100 | 1.245 |
10:24 ET | 1204 | 1.24 |
10:26 ET | 779 | 1.23 |
10:28 ET | 200 | 1.23 |
10:30 ET | 400 | 1.235 |
10:32 ET | 200 | 1.235 |
10:33 ET | 2450 | 1.21 |
10:35 ET | 100 | 1.22 |
10:37 ET | 4600 | 1.23 |
10:44 ET | 900 | 1.23 |
10:46 ET | 4113 | 1.23 |
10:48 ET | 2700 | 1.22 |
10:50 ET | 3101 | 1.2201 |
10:51 ET | 800 | 1.22 |
10:53 ET | 2300 | 1.22 |
10:55 ET | 4317 | 1.2201 |
10:57 ET | 1000 | 1.22 |
11:00 ET | 2900 | 1.22 |
11:02 ET | 2700 | 1.22 |
11:04 ET | 1800 | 1.225 |
11:06 ET | 42400 | 1.225 |
11:08 ET | 200 | 1.225 |
11:09 ET | 200 | 1.22 |
11:11 ET | 200 | 1.225 |
11:13 ET | 1544 | 1.225 |
11:15 ET | 17770 | 1.215 |
11:18 ET | 3675 | 1.21 |
11:20 ET | 2200 | 1.215 |
11:22 ET | 100 | 1.21 |
11:24 ET | 3450 | 1.215 |
11:26 ET | 500 | 1.215 |
11:27 ET | 13202 | 1.215 |
11:29 ET | 600 | 1.21 |
11:31 ET | 11357 | 1.22 |
11:33 ET | 17400 | 1.215 |
11:36 ET | 10592 | 1.215 |
11:40 ET | 12052 | 1.23 |
11:42 ET | 300 | 1.23 |
11:44 ET | 100 | 1.2301 |
11:45 ET | 2034 | 1.235 |
11:47 ET | 100 | 1.235 |
11:49 ET | 40200 | 1.235 |
11:51 ET | 200 | 1.235 |
11:54 ET | 100 | 1.235 |
11:56 ET | 200 | 1.235 |
11:58 ET | 410 | 1.2399 |
12:00 ET | 300 | 1.23 |
12:02 ET | 300 | 1.235 |
12:03 ET | 200 | 1.235 |
12:05 ET | 500 | 1.2399 |
12:07 ET | 1273 | 1.235 |
12:09 ET | 200 | 1.235 |
12:12 ET | 300 | 1.235 |
12:14 ET | 300 | 1.235 |
12:16 ET | 200 | 1.235 |
12:18 ET | 100 | 1.235 |
12:20 ET | 700 | 1.235 |
12:21 ET | 399 | 1.235 |
12:23 ET | 1400 | 1.2347 |
12:25 ET | 10740 | 1.225 |
12:27 ET | 900 | 1.22 |
12:30 ET | 2432 | 1.22 |
12:32 ET | 1438 | 1.22 |
12:34 ET | 1852 | 1.21 |
12:36 ET | 808 | 1.21 |
12:38 ET | 6478 | 1.21 |
12:39 ET | 3000 | 1.21 |
12:41 ET | 2654 | 1.21 |
12:43 ET | 1100 | 1.22 |
12:45 ET | 2500 | 1.21 |
12:48 ET | 1363 | 1.22 |
12:50 ET | 700 | 1.21 |
12:52 ET | 1100 | 1.21 |
12:54 ET | 22426 | 1.22 |
12:56 ET | 700 | 1.215 |
12:57 ET | 1226 | 1.22 |
12:59 ET | 1100 | 1.22 |
01:01 ET | 700 | 1.22 |
01:03 ET | 1428 | 1.215 |
01:06 ET | 1600 | 1.21 |
01:08 ET | 1328 | 1.21 |
01:10 ET | 700 | 1.215 |
01:12 ET | 2100 | 1.21 |
01:14 ET | 700 | 1.22 |
01:15 ET | 900 | 1.21 |
01:17 ET | 1153 | 1.22 |
01:19 ET | 500 | 1.22 |
01:21 ET | 18141 | 1.205 |
01:24 ET | 4921 | 1.205 |
01:26 ET | 5161 | 1.2 |
01:28 ET | 420 | 1.2 |
01:30 ET | 20700 | 1.2 |
01:32 ET | 1500 | 1.204 |
01:33 ET | 755 | 1.2091 |
01:35 ET | 1998 | 1.2 |
01:37 ET | 1000 | 1.21 |
01:39 ET | 9871 | 1.205 |
01:42 ET | 18688 | 1.21 |
01:44 ET | 400 | 1.2 |
01:46 ET | 800 | 1.2 |
01:48 ET | 782 | 1.205 |
01:50 ET | 1300 | 1.205 |
01:51 ET | 500 | 1.21 |
01:53 ET | 1157 | 1.21 |
01:55 ET | 893 | 1.2 |
01:57 ET | 133051 | 1.205 |
02:00 ET | 521 | 1.2099 |
02:02 ET | 2200 | 1.21 |
02:04 ET | 800 | 1.21 |
02:06 ET | 1100 | 1.21 |
02:08 ET | 2876 | 1.215 |
02:09 ET | 1211 | 1.215 |
02:11 ET | 600 | 1.22 |
02:13 ET | 300 | 1.22 |
02:15 ET | 700 | 1.22 |
02:18 ET | 400 | 1.22 |
02:20 ET | 261 | 1.22 |
02:22 ET | 744 | 1.22 |
02:24 ET | 600 | 1.22 |
02:26 ET | 6426 | 1.22 |
02:27 ET | 1958 | 1.21 |
02:29 ET | 300 | 1.22 |
02:31 ET | 223 | 1.215 |
02:33 ET | 750 | 1.22 |
02:36 ET | 7628 | 1.23 |
02:38 ET | 3230 | 1.24 |
02:40 ET | 200 | 1.25 |
02:42 ET | 1800 | 1.25 |
02:44 ET | 950 | 1.25 |
02:45 ET | 1500 | 1.245 |
02:47 ET | 100 | 1.25 |
02:49 ET | 2920 | 1.26 |
02:51 ET | 100 | 1.255 |
02:54 ET | 3200 | 1.26 |
02:56 ET | 950 | 1.26 |
02:58 ET | 200 | 1.255 |
03:00 ET | 800 | 1.26 |
03:02 ET | 200 | 1.26 |
03:03 ET | 1267 | 1.26 |
03:05 ET | 4301 | 1.26 |
03:07 ET | 400 | 1.26 |
03:09 ET | 1608 | 1.26 |
03:12 ET | 14136 | 1.255 |
03:14 ET | 9998 | 1.28 |
03:16 ET | 2694 | 1.28 |
03:18 ET | 100 | 1.28 |
03:20 ET | 7402 | 1.26 |
03:21 ET | 2200 | 1.25 |
03:23 ET | 3264 | 1.25 |
03:25 ET | 1115 | 1.255 |
03:27 ET | 100 | 1.255 |
03:30 ET | 1578 | 1.255 |
03:32 ET | 975 | 1.258 |
03:34 ET | 553 | 1.25 |
03:36 ET | 3644 | 1.25 |
03:38 ET | 600 | 1.255 |
03:39 ET | 3970 | 1.26 |
03:41 ET | 11339 | 1.26 |
03:43 ET | 1800 | 1.26 |
03:45 ET | 800 | 1.26 |
03:48 ET | 23936 | 1.23 |
03:50 ET | 7905 | 1.23 |
03:52 ET | 16722 | 1.235 |
03:54 ET | 18229 | 1.22 |
03:56 ET | 5691 | 1.22 |
03:57 ET | 12686 | 1.22 |
03:59 ET | 83377 | 1.22 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Shattuck Labs Inc | 58.2M | -0.7x | --- |
Barinthus Biotherapeutics PLC | 52.4M | -0.8x | --- |
Mural Oncology PLC | 57.2M | -0.3x | --- |
Aerovate Therapeutics Inc | 59.2M | -0.7x | --- |
Serina Therapeutics Inc | 60.4M | -0.7x | --- |
Regencell Bioscience Holdings Ltd | 56.6M | -12.0x | --- |
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $58.2M |
---|---|
Revenue (TTM) | $4.1M |
Shares Outstanding | 47.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.82 |
EPS | $-1.85 |
Book Value | $3.06 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | 14.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,195.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.